anti-CD33 CAR T-cell therapy (Ziopharm Oncology/Precigen)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug Nameanti-CD33 CAR T-cell therapy (Ziopharm Oncology/Precigen)
Drug Alias NameINXN-3004 Viral CAR-Tanti-CD33 CAR T-cell therapy (Ziopharm Oncology/Intrexon)autologous T cell therapy (ZIOPHARM Oncology Inc)INXN-3004
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionMyeloid cell surface antigen CD33 modulators
TargetsMyeloid cell surface antigen CD33
Therapy Area/IndicationsLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAlaunos Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAlaunos Therapeutics IncPrecigen Inc
Active IndicationsN/A
Inactive IndicationsLeukemia, Myeloid, Acute

Other Information

ATC CodeN/A
Related LinksN/A